Valuing Hyaluronic Acid in Aesthetics

Hyaluronic acid is the quiet workhorse of the UK aesthetics sector. It sits behind the majority of injectable treatments booked in clinics and salons across the country, yet many business owners and practitioners underestimate just how much of their reputation, revenue and regulatory exposure rests on this single molecule. Understanding the true value of hyaluronic acid, both as a clinical tool and as a commercial asset, is now essential rather than optional.

Our latest post is aimed at aesthetics business owners, practitioners and employers who buy, store and use hyaluronic acid products, whether that is crosslinked dermal fillers, non-crosslinked skin boosters, or bio-remodelling injectables. It covers what hyaluronic acid actually is, how it works, where it sits in the shifting UK regulatory landscape as of 2026, and the practical steps that protect both your clients and your business.

What Is Hyaluronic Acid and Why Does It Matter?

Hyaluronic acid, often shortened to HA, is a naturally occurring sugar molecule found throughout the human body. In the skin it binds water, supports volume and helps maintain elasticity. Production begins to decline from the mid-twenties onwards, which is the underlying reason demand for HA-based treatments continues to grow.

In a clinical setting, HA is prized for three qualities that few other injectable materials share:

• Biocompatibility. Because HA occurs naturally in the body, the risk of allergic reaction is low compared with older synthetic materials.
• Reversibility. HA-based products can be dissolved using the enzyme hyaluronidase, giving practitioners a genuine safety net that non-HA fillers such as calcium hydroxylapatite or poly-L-lactic acid do not offer.
• Versatility. By adjusting the degree of crosslinking, manufacturers can produce anything from a firm structural gel to a thin, spreadable hydrating fluid.

That versatility is exactly why HA appears across such a wide product range, and why valuing it correctly means understanding the differences between product types rather than treating them as interchangeable.

Dermal Fillers vs Skin Boosters: The Value Lies in the Formulation

The single most important technical distinction for any HA product is crosslinking. This determines how the gel behaves once injected, how long it lasts, and ultimately what you can charge for it.

Crosslinked HA: Dermal Fillers

Dermal fillers use crosslinked hyaluronic acid, where the molecules are chemically bonded to create a firmer, more structured gel. This gel stays where it is placed, which is precisely what makes it suitable for restoring volume, defining contours and refining features. Common uses include cheek volume, lip enhancement, softening nasolabial folds and non-surgical nose refinement. Brands such as Revolax, Neuramis and E.P.T.Q. sit in this category.

Non-Crosslinked or Lightly Crosslinked HA: Skin Boosters and Bio-Remodellers

Skin boosters use non-crosslinked or minimally crosslinked HA, making them thinner and designed to spread through the tissue rather than hold shape. Rather than adding structure, they improve skin quality, hydration and texture, and many stimulate the skin’s own collagen and elastin over time. This is why they are often described as injectable skincare. Products in this space frequently pair HA with amino acids or other actives, and this category also overlaps with polynucleotide treatments.

A simple way to hold the distinction in mind: dermal fillers change the shape of the skin, while skin boosters change the behaviour of the skin. Both use the same base molecule, but they are not the same treatment and should never be sold as such.

Communicating this difference accurately is not just good practice, it is a compliance issue. Overstating what a product does, or blurring the line between structural and hydrating outcomes, exposes a business to advertising and misrepresentation risk.

Where Hyaluronic Acid Sits in UK Regulation

This is the area where the value of HA products intersects most sharply with legal and financial risk, and it is changing quickly.

HA-based dermal fillers are currently classified as medical devices, not medicines. This classification came into force in May 2020 and means fillers fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA). Crucially, and unlike botulinum toxin, dermal fillers are not prescription-only, which is why non-medical practitioners can currently administer them legally. The MHRA has, however, signalled its intention to expand the scope of the UK Medical Device Regulations to bring products marketed for aesthetic purposes, including dermal fillers, more firmly under device regulation, so this position should be treated as evolving.

The Proposed Licensing Scheme for England

The regulatory framework is under active review. In 2023 the government consulted on an aesthetics licensing scheme, and on 7 August 2025 it published its response, confirming a red, amber and green (RAG) risk model. Under these proposals, most dermal fillers and toxin treatments are expected to fall into the amber tier, requiring a licensed and appropriately trained practitioner under local authority licensing, with the highest-risk red procedures restricted to regulated healthcare professionals in Care Quality Commission (CQC) registered premises.

It is important to be accurate about the status here. As of 2026 the national licensing scheme in England is not yet in force and there is no confirmed commencement date. Further consultation and secondary legislation are still expected before it lands. It is also worth clarifying that CQC’s regulated-activity scope has so far been extended only to a small number of high-risk procedures, such as certain intimate-area and genital augmentation treatments, and does not currently bring standard facial dermal fillers or facial botulinum toxin into CQC regulation. The sensible commercial position is to operate now as though the scheme is already live.

Prescribing and Supply Chain Changes Already in Force

While the licensing scheme waits in the wings, two changes affecting the wider injectable supply chain are already live and matter to any clinic offering both toxin and HA treatments:

• Remote prescribing ban. Since 1 June 2025, remote prescribing of cosmetic injectables has been prohibited. Professional regulators including the NMC now require a face-to-face consultation with the prescriber before a prescription-only medicine is issued for cosmetic use.
• Tighter supply arrangements. From July 2026, non-prescribing practitioners can no longer obtain prescription-only medicines for cosmetic use through a “prescribe and supply” arrangement with a remote prescriber who has never assessed the client in person. The client must have had an in-person consultation with the prescribing clinician.

HA dermal fillers are not prescription-only medicines, so these rules bite hardest on toxin work. However, most clinics run mixed treatment menus, so understanding both is part of running a defensible business.

Under-18s: A Standing Legal Restriction

One rule has been settled for several years and applies directly to fillers. Under the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021, which came into force on 1 October 2021, it is a criminal offence in England to administer botulinum toxin or cosmetic fillers by injection for a cosmetic purpose to anyone under 18, or to make arrangements to do so, other than by an approved medical professional. This applies regardless of parental consent.

Practical Regulatory Points for Business Owners

• Local authority licensing. Some treatments already require registration with your local authority and may be subject to premises inspection by Environmental Health Officers. What is covered varies by council, so contact your local licensing department directly.
• Supply chain control. The route by which you buy HA products is tightening. Purchasing only from verified, reputable trade suppliers protects both product integrity and your audit trail.
• Emergency provision. Access to hyaluronidase for dissolving HA filler, alongside appropriate emergency protocols, is increasingly treated as a baseline standard rather than a nice-to-have.
• Training benchmarks. Industry bodies including the Joint Council for Cosmetic Practitioners (JCCP) continue to push a Level 7 standard for injectables as the expected benchmark for filler work.